力生制藥 (002393.SZ)

15.81 +0.02 (+0.13%) 收市：03:04PM CST

力生制藥

No.16, Saida North Road
Xiqing Eco & Tech Dev Zn
Tianjin 300385
China
86 22 2764 1760
https://www.lishengpharma.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 1,328

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Fujun Wang	GM & Non-Independent Director	無	無	1968
Mr. Jiaying Wang	Financial Director & Accounting Supervisor	無	無	1982
Ms. Feifei Ma	Secretary of the Board	無	無	1980
Mr. Changfeng Long	Chief Engineer & Deputy GM	無	無	1975
Ms. Xiaoyan Guo	Deputy General Manager	無	無	1974
Mr. Jiankang Liang	Deputy General Manager	無	無	1974

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 CNY。

描述

Tianjin Lisheng Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. It offers its products in various forms comprising tablets, soft and hard capsules, granules, dripping pills, freeze-dried powder injections, and water injections for use in various therapeutic fields, such as circulatory system, systemic anti-infection, digestive system, nervous and endocrine system, respiratory system, musculoskeletal, and genitourinary system, as well as antitumor and immune system modulation, and big health series products. The company also provides Chinese and Western medicines; biological preparations, oral liquids, and raw materials; and intermediates, diagnostic reagents, biochemical reagents, plastic bottles, and raw materials. It also exports its products. The company was founded in 1951 and is based in Tianjin, China. Tianjin Lisheng Pharmaceutical Co.,Ltd. operates as a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd.

公司管治

截至 無 止，力生制藥 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。